Evidence-based radiation oncology: Oesophagus

Radiotherapy and Oncology

Volumn 92, Issue 2, 2009, Pages 276-290

  Berger, Bernhard ^a   Belka, Claus ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemoradiation; Multimodality treatment; Neoadjuvant treatment; Oesophageal cancer; Radiochemotherapy; Radiotherapy; Surgery

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSIMETRY; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ESOPHAGEAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; NEOADJUVANT THERAPY; PALLIATIVE CARE;

EID: 67650970450     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.02.019     Document Type: Review

References (141)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
3. DeMeester S.R. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 13 (2006) 12-30
4. Brenner B., Ilson D.H., and Minsky B.D. Treatment of localized esophageal cancer. Semin Oncol 31 (2004) 554-565
5. Koshy M., Esiashvilli N., Landry J.C., Thomas Jr. C.R., and Matthews R.H. Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist 9 (2004) 147-159
6. Mariette C., and Triboulet J.P. Should resectable esophageal cancer be resected?. Ann Surg Oncol 13 (2006) 447-449
7. Mariette C., Piessen G., and Triboulet J.P. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8 (2007) 545-553
8. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual. 6th ed. (2002), Springer, New York p. 201-346
9. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
10. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 (2005) 142-146
11. Brown L.M., Hoover R., Silverman D., et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 153 (2001) 114-122
12. Fukuzawa K., Noguchi Y., Yoshikawa T., et al. High incidence of synchronous cancer of the oral cavity and the upper gastrointestinal tract. Cancer Lett 144 (1999) 145-151
13. Solaymani-Dodaran M., Logan R.F., West J., Card T., and Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53 (2004) 1070-1074
14. Siewert R.J., Stein H.J., Feith M., Bruecher B.L., Bartels H., and Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg 234 (2001) 360-367
15. Stein H.J., Feith M., Bruecher B.L., Naehrig J., Sarbia M., and Siewert J.R. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 242 (2005) 566-573
16. Wijnhoven B.P., Siersema P.D., Hop W.C., van Dekken H., and Tilanus H.W. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 86 (1999) 529-535
17. Siewert J.R., and Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998) 1457-1459
18. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
19. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
20. Dolan K., Sutton R., Walker S.J., Morris A.I., Campbell F., and Williams E.M. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 80 (1999) 834-842
21. O'Sullivan G.C., Sheehan D., Clarke A., et al. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 116 (1999) 543-548
22. Mandard A.M., Chasle J., Marnay J., et al. Autopsy findings in 111 cases of esophageal cancer. Cancer 48 (1981) 329-335
23. Chan K.W., Chan E.Y., and Chan C.W. Carcinoma of the esophagus. An autopsy study of 231 cases. Pathology 18 (1986) 400-405
24. Mariette C., Balon J.M., Piessen G., Fabre S., Van Seuningen I., and Triboulet J.P. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 97 (2003) 1616-1623
25. Earlam R., and Cunha-Melo J.R. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67 (1980) 381-390
26. Earlam R., and Cunha-Melo J.R. Oesophageal squamous cell carcinomas: II. A critical view of radiotherapy. Br J Surg 67 (1980) 457-461
27. Hulscher J.B., Tijssen J.G., Obertop H., and van Lanschot J.J. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 72 (2001) 306-313
28. Hulscher J.B., van Sandick J.W., de Boer A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347 (2002) 1662-1669
29. Isono K., Ochiai T., Okuyama K., and Onoda S. The treatment of lymph node metastasis from esophageal cancer by extensive lymphadenectomy. Jpn J Surg 20 (1990) 151-157
30. Nishihira T., Hirayama K., and Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 175 (1998) 47-51
31. Altorki N., and Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma?. Ann Surg 234 (2001) 581-587
32. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
33. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
34. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
35. Sun D.R. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 16 (1989) 329-334
36. Nemoto K., Yamada S., Hareyama M., Nagakura H., and Hirokawa Y. Radiation therapy for superficial esophageal cancer: a comparison of radiotherapy methods. Int J Radiat Oncol Biol Phys 50 (2001) 639-644
37. Sykes A.J., Burt P.A., Slevin N.J., Stout R., and Marrs J.E. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 48 (1998) 15-21
38. Fok M., McShane J., Law S.Y.K., and Wong J. Prospective randomised study on radiotherapy and surgery in the treatment of oesophageal carcinoma. Asian J Surg 17 (1994) 223-229
39. Badwe R.A., Sharma V., Bhansali M.S., et al. The quality of swallowing for patients with operable esophageal carcinoma: a randomized trial comparing surgery with radiotherapy. Cancer 85 (1999) 763-768
40. Malthaner R.A., Wong R.K., Rumble R.B., Zuraw L., and Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2 (2004) 35
41. Yu J., Ren R., Sun X., Yin Y., and Fu F. A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer. Proc Am Soc Clin Oncol 24 (2006) 4013
42. Suntharalingam M. Definitive chemoradiation in the management of locally advanced esophageal cancer. Semin Radiat Oncol 17 (2007) 22-28
43. Coia L.R., Engstrom P.F., Paul A.R., Stafford P.M., and Hanks G.E. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20 (1991) 29-36
44. Herskovic A., Martz K., al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (1992) 1593-1598
45. al-Sarraf M., Martz K., Herskovic A., et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15 (1997) 277-284
46. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281 (1999) 1623-1627
47. Wong R., and Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev (2006) CD002092
48. Minsky B.D., Neuberg D., Kelsen D.P., et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 43 (1999) 517-523
49. Minsky B.D., Pajak T.F., Ginsberg R.J., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002) 1167-1174
50. Gaspar L.E., Qian C., Kocha W.I., Coia L.R., Herskovic A., and Graham M. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report. Int J Radiat Oncol Biol Phys 37 (1997) 593-599
51. Shi X.H., Yao W., and Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 51 (1999) 21-26
52. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005) 2310-2317
53. Bedenne L., Michel P., Bouche O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25 (2007) 1160-1168
54. Zhang Z., Liao Z., Jin J., et al. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61 (2005) 656-664
55. Geh J.I., Bond S.J., Bentzen S.M., and Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 78 (2006) 236-244
56. Ilson D.H., Ajani J., Bhalla K., et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16 (1998) 1826-1834
57. Ilson D.H., Saltz L., Enzinger P., et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17 (1999) 3270-3275
58. Michel P., Adenis A., Di Fiore F., et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer 95 (2006) 705-709
59. Murakami M., Kuroda Y., Nakajima T., et al. Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma. Int J Radiat Oncol Biol Phys 45 (1999) 277-284
60. Chan A., and Wong A. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?. Int J Radiat Oncol Biol Phys 45 (1999) 265-270
61. Chiu P.W., Chan A.C., Leung S.F., et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 9 (2005) 794-802
62. Teniere P., Hay J.M., Fingerhut A., and Fagniez P.L. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 173 (1991) 123-130
63. Fok M., Sham J.S., Choy D., Cheng S.W., and Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 113 (1993) 138-147
64. Zieren H.U., Muller J.M., Jacobi C.A., Pichlmaier H., Muller R.P., and Staar S. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 19 (1995) 444-449
65. Xiao Z.F., Yang Z.Y., Liang J., et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 75 (2003) 331-336
66. Yu E., Dar R., Rodrigues G.B., et al. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?. Radiother Oncol 73 (2004) 141-148
67. Pouliquen X., Levard H., Hay J.M., McGee K., Fingerhut A., and Langlois-Zantin O. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg 223 (1996) 127-133
68. Ando N., Iizuka T., Kakegawa T., et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 114 (1997) 205-209
69. Ando N., Iizuka T., Ide H., et al. Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 21 (2003) 4592-4596
70. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23 (2005) 4330-4337
71. Ancona E., Ruol A., Santi S., et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91 (2001) 2165-2174
72. Nygaard K., Hagen S., Hansen H.S., et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16 (1992) 1104-1109
73. Arnott S.J., Duncan W., Gignoux M., et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 41 (1998) 579-583
74. Kelsen D.P., Winter K.A., Gunderson L.L., et al. Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25 (2007) 3719-3725
75. Urschel J.D., Vasan H., and Blewett C.J. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 183 (2002) 274-279
76. Gebski V., Burmeister B., Smithers B.M., Foo K., Zalcberg J., Simes J., and Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8 (2007) 226-234
77. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., and Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
78. Burmeister B.H., Smithers B.M., Gebski V., et al. Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6 (2005) 659-668
79. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26 (2008) 1086-1092
80. Funk E.M., and Witte J. Multimodal therapy for esophageal adenocarcinoma. N Engl J Med 336 (1997) 375
81. Badwe R.A., Vaidya J.S., and Bhansali M.S. Multimodal therapy for esophageal adenocarcinoma. N Engl J Med 336 (1997) 374-375
82. Kaklamanos I.G., Walker G.R., Ferry K., Franceschi D., and Livingstone A.S. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 10 (2003) 754-761
83. Urschel J.D., and Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185 (2003) 538-543
84. Fiorica F., Di Bona D., Schepis F., et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53 (2004) 925-930
85. Stahl M., Walz K.M., Stuschke M., et al. Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: first results of a randomized phase III trial. Proc Am Soc Clin Oncol 25 (2007) 4511
86. Ilson D.H. Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword?. J Clin Oncol 25 (2007) 1155-1156
87. Bonnetain F., Bouche O., Michel P., et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 17 (2006) 827-834
88. Schneider B.J., and Urba S.G. Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care?. Semin Radiat Oncol 17 (2007) 45-52
89. Swisher S.G., Wynn P., Putnam J.B., et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123 (2002) 175-183
90. Tomimaru Y., Yano M., Takachi K., et al. Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol 93 (2006) 422-428
91. Cerfolio R.J., Bryant A.S., Ohja B., Bartolucci A.A., and Eloubeidi M.A. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129 (2005) 1232-1241
92. Westerterp M., van Westreenen H.L., Reitsma J.B., et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 236 (2005) 841-851
93. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
94. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
95. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 (2006) 4692-4698
96. Bhargava P., Reich P., Alavi A., and Zhuang H. Radiation-induced esophagitis on FDG PET imaging. Clin Nucl Med 28 (2003) 849-850
97. Erasmus J.J., Munden R.F., Truong M.T., et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1 (2006) 478-486
98. Wieder H.A., Brucher B.L., Zimmermann F., et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22 (2004) 900-908
99. Nakamura R., Obara T., Katsuragawa S., et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med 20 (2002) 181-186
100. Withers H.R., Taylor J.M., and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
101. Kajanti M., Kaleta R., Kankaanranta L., Muhonen T., and Holsti L. Effect of overall treatment time on local control in radical radiotherapy for squamous cell carcinoma of esophagus. Int J Radiat Oncol Biol Phys 32 (1995) 1017-1023
102. Hong T.S., Crowley E.M., Killoran J., and Mamon H.J. Considerations in treatment planning for esophageal cancer. Semin Radiat Oncol 17 (2007) 53-61
103. Hosch S.B., Stoecklein N.H., Pichlmeier U., et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 19 (2001) 1970-1975
104. Gao X.S., Qiao X., Wu F., et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67 (2007) 389-396
105. Vrieze O., Haustermans K., De Wever W., et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 73 (2004) 269-275
106. Konski A., Doss M., Milestone B., et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 1123-1128
107. Moureau-Zabotto L., Touboul E., Lerouge D., et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) 340-345
108. Dieleman E.M., Senan S., Vincent A., et al. Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys 67 (2007) 775-780
109. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54 (2002) 329-339
110. Wang S., Liao Z., Wei X., et al. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 3 (2008) 277-282
111. Wang S.L., Liao Z., Vaporciyan A.A., et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64 (2006) 692-699
112. Chandra A., Guerrero T.M., Liu H.H., et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77 (2005) 247-253
113. Chen Y.J., Liu A., Han C., et al. Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim 32 (2007) 166-171
114. Nutting C.M., Bedford J.L., Cosgrove V.P., Tait D.M., Dearnaley D.P., and Webb S. A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol 61 (2001) 157-163
115. Taremi M., Ringash J., and Dawson L.A. Upper abdominal malignancies: intensity-modulated radiation therapy. Front Radiat Ther Oncol 40 (2007) 272-288
116. Meluch A.A., Greco F.A., Gray J.R., et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 9 (2003) 251-260
117. Roof K.S., Coen J., Lynch T.J., et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1120-1128
118. Kelsey C.R., Chino J.P., Willett C.G., et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys 69 (2007) 770-776
119. Chiarion-Sileni V., Corti L., Ruol A., et al. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer 96 (2007) 432-438
120. Itakura Y., Sasano H., Shiga C., et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74 (1994) 795-804
121. Ross J.S., and McKenna B.J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19 (2001) 554-568
122. Dragovich T., McCoy S., Fenoglio-Preiser C.M., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24 (2006) 4922-4927
123. Pinto C., Di Fabio F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18 (2007) 510-517
124. Safran H., Dipetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 67 (2007) 405-409
125. Safran H., Suntharalingam M., Dipetrillo T., et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70 (2008) 391-395
126. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354 (2006) 567-578
127. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25 (2007) 2171-2177
128. Grünberger B., Raderer M., Schmidinger M., and Hejna M. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res 27 (2007) 2705-2714
129. Enzinger P.C., Ilson D.H., and Kelsen D.P. Chemotherapy in esophageal cancer. Semin Oncol 26 (1999) 12-20
130. Kelsen D., Ginsberg R., Bains M., et al. A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Semin Oncol 24 (1997) S77-S81
131. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 (2002) 1996-2004
132. Homs M.Y., v d Gaast A., Siersema P.D., Steyerberg E.W., and Kuipers E.J. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev (2006) CD004063
133. Adam A., Ellul J., Watkinson A.F., et al. Palliation of inoperable esophageal carcinoma: a prospective randomized trial of laser therapy and stent placement. Radiology 202 (1997) 344-348
134. Sur R.K., Donde B., Levin V.C., and Mannell A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int J Radiat Oncol Biol Phys 40 (1998) 447-453
135. Homs M.Y., Steyerberg E.W., Eijkenboom W.M., et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 364 (2004) 1497-1504
136. Bergquist H., Wenger U., Johnsson E., et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 18 (2005) 131-139
137. Steyerberg EW, Homs MY, Stokvis A, Essink-Bot ML, Siersema PD; for the SIREC Study Group. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc 2005;62:333-340.
138. Sur R.K., Levin C.V., Donde B., Sharma V., Miszczyk L., and Nag S. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma - an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys 53 (2002) 127-133
139. Sur R., Donde B., Falkson C., et al. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy 3 (2004) 191-195
140. Harvey J.A., Bessell J.R., Beller E., et al. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Dis Esophagus 17 (2004) 260-265
141. Hayter C.R., Huff-Winters C., Paszat L., Youssef Y.M., Shelley W.E., and Schulze K. A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. Radiother Oncol 56 (2000) 329-333